Dmitry Balyasny’s Fulgent Genetics FLGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.13M Buy
+55,078
New +$934K ﹤0.01% 2140
2025
Q3
Sell
-16,097
Closed -$320K 3077
2025
Q2
$320K Sell
16,097
-53,329
-77% -$1.04M ﹤0.01% 2464
2025
Q1
$1.17M Buy
69,426
+43,113
+164% +$734K ﹤0.01% 1927
2024
Q4
$486K Buy
+26,313
New +$514K ﹤0.01% 2202
2024
Q2
Sell
-10,994
Closed -$239K 2736
2024
Q1
$239K Buy
+10,994
New +$273K ﹤0.01% 2342
2023
Q3
Sell
-8,609
Closed -$319K 2404
2023
Q2
$319K Buy
+8,609
New +$300K ﹤0.01% 1974
2023
Q1
Sell
-13,700
Closed -$408K 2820
2022
Q4
$408K Sell
13,700
-20,333
-60% -$728K ﹤0.01% 1907
2022
Q3
$1.3M Buy
34,033
+1,331
+4% +$66.7K ﹤0.01% 1694
2022
Q2
$1.78M Buy
+32,702
New +$1.8M 0.01% 1475
2021
Q4
Sell
-2,962
Closed -$266K 2356
2021
Q3
$266K Buy
+2,962
New +$269K ﹤0.01% 1612

Other funds holding FLGT

Dmitry Balyasny's FLGT Position: Q2 2026 in Review

Dmitry Balyasny opened a new position in Fulgent Genetics (FLGT) in Q2 2026: 55,078 shares worth $1.13M. The stake represents ﹤0.01% of the portfolio and ranks #2140 among its holdings. This is a return to the name: Dmitry Balyasny previously reported a position in FLGT as recently as Q2 2025.

Dmitry Balyasny first reported a position in FLGT in Q3 2021 and has held it in 10 quarters since. The position peaked at $1.78M in Q2 2022. 141 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.

  • Dmitry Balyasny held 55,078 shares of Fulgent Genetics worth $1.13M as of Q2 2026.
  • Fulgent Genetics was a new Dmitry Balyasny position in Q2 2026.
  • Fulgent Genetics made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #2140 holding.
  • Dmitry Balyasny first reported a position in Fulgent Genetics in Q3 2021 and has held it in 10 quarters since.
  • Dmitry Balyasny's Fulgent Genetics position peaked at $1.78M in Q2 2022.
  • 141 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.